Cytonome

Cell Sorting Instrumentscytonome.com

Company typePrivate
Founded2009
HeadquartersBedford, United States
Headcount101–250
GTM typeB2B
OfferingHardware or Manufacturing

Cytonome firmographics

Firmographics

Name: Cytonome
Legal name: Cytonome/ST LLC
Website: https://cytonome.com
Company type: Private
Founded year: 2009
Operating status: Operating
Headcount range: 101–250 employees
Ownership category
akta.pro rank

Cytonome industry classification

Industry

Product category: Cell Sorting Instruments
NAICS: Analytical Laboratory Instrument Manufacturing (334516), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
SIC: Surgical & Medical Instruments & Apparatus (3841)
akta.pro primary industry: Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish) (HLAAABAG)
akta.pro secondary industries: Microscopy, Imaging & Flow Cytometry Instruments (HLAGAIAE), Cell Therapy Manufacturing Services (GMP, autologous/allogeneic) (HLAAAKAC)

Keywords

Cell sorting instruments
Microfluidic cell purification
Cell therapy manufacturing
Jet-in-air cell sorting
GMP consumables

Where Cytonome is headquartered

Location

Headquarters

HQ city: Bedford
HQ country: United States
HQ region: North America

Offices3 records

Markets served

Cytonome business model

Business model

GTM type: B2B
Offering type: Hardware or Manufacturing
Cost components: Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales

Revenue model

Cell Sorting Equipment Sales: Cytonome designs and manufactures high performance cell sorting technologies (GigaSort and Hydris platforms) for cell therapy manufacturing and industrial sorting applications. Revenue is generated through hardware sales of cell sorting instruments and associated consumables.
GMP Consumables: Single-use, gamma-irradiated consumables for GigaSort microfluidic cell sorting manufactured under ISO 13485:2016 compliant QMS. Provides recurring consumable revenue alongside instrument sales.
Cytometry Software: Software solutions through acquired Verity Software House (2021) providing cytometry software expertise for data analysis and processing alongside hardware offerings.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Cytonome product offering

Product offering

Core offering

Cytonome designs and manufactures high-performance cell sorting instruments for cell therapy manufacturing and industrial sorting applications. Its two core platforms are GigaSort, a microfluidic cell sorter for closed-system GMP cell therapy manufacturing, and Hydris, an industrial-scale jet-in-air cell sorting system. The company also produces single-use gamma-irradiated consumables and cytometry software (via Verity Software House).

Product overview

Cytonome offers a portfolio of two distinct cell sorting platforms: GigaSort and Hydris. GigaSort is a microfluidic-based cell sorter designed for cell therapy manufacturing, featuring a closed-system single-use consumable for GMP operations with gentle cell processing at high throughput. Hydris is an industrial-scale jet-in-air cell sorting solution that leverages parallelism and advanced automation for high-volume commercial applications. Together, these platforms serve the cell therapy manufacturing market and industrial sorting applications across a dozen countries.

Differentiator

Problem solved

Functional benefit

Products and services

GigaSort

Quantifiable outcome

500 million cells processed in approximately 6 hours
+2 more outcomes

Companies that use Cytonome

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Cytonome technology and API

Technology

Technology focussed Yes

API detail

Has API: No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Cytonome partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered flagship and core.

Sumitomo PharmaflagshipTechnology or Integration · 11 March 2026Sumitomo Pharma received regulatory approval for the world's first iPS cell-derived regenerative medicine therapy for Parkinson's disease. Cytonome's GigaSort microfluidic cell isolation platform played a critical role in the program's manufacturing workflow, enabling gentle, consistent cell processing at commercial scale for GMP operations. This landmark approval demonstrates the platform's regulatory acceptance.
Verity Software HousecoreTechnology or Integration · 1 January 2021Cytonome expanded software capability in 2021 through acquisition of Verity Software House, the cytometry software experts. This acquisition provides integrated software solutions for cytometry data analysis alongside hardware offerings.
STgeneticsflagshipOthersSTgenetics is the global parent company of Cytonome and a major shareholder. STgenetics is an international leader of livestock reproductive services and the primary customer deploying Hydris platform commercially. Over 1000 Hydris units are in use by STgenetics operations globally.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Cytonome competitors and assessment

Company assessment

Emerging players

Cellares: Cellares builds automated cell therapy manufacturing workstations (Cell Shuttle) integrating upstream and downstream cell processing steps. It is an emerging player in the GMP cell therapy manufacturing automation space adjacent to Cytonome's GigaSort workflow.
Union Biometrica: Union Biometrica manufactures COPAS and BioSorter flow cytometry platforms specialized for large cells and organisms. It overlaps with Cytonome's niche capability of sorting large/adherent cells like neurons and similar challenging biological entities.
Curiox Biosystems: Curiox develops automated cell processing and washing platforms using microfluidic technology for cell therapy manufacturing. It is an emerging player in the GMP-friendly microfluidic cell processing space overlapping with Cytonome's GigaSort platform.

Others

10x Genomics: 10x Genomics provides single-cell analysis platforms used extensively in cell therapy R&D and characterization workflows. It is an adjacent life sciences tool provider serving overlapping biopharma customers rather than directly competing in cell sorting hardware.

Direct peers

Sony Biotechnology: Sony Biotechnology manufactures the SH800 and MA900 cell sorters with microfluidic chip-based sorting technology directly competing with Cytonome's GigaSort. Both target cell therapy developers and biopharma with GMP-friendly closed-system sorters.

Broad incumbents

Bio-Rad Laboratories: Bio-Rad's S3e and ZE5 cell sorters serve research and biopharma flow cytometry markets. As a broader life sciences instrumentation company, Bio-Rad overlaps with Cytonome in cell sorting instrumentation for cell therapy and biotech applications.
Thermo Fisher Scientific (Life Sciences): Thermo Fisher offers the Bigfoot cell sorter and a broad portfolio of flow cytometry instruments and consumables serving cell therapy manufacturing. As a diversified life sciences incumbent, it competes with Cytonome in pharma/biotech instrumentation.
Miltenyi Biotec: Miltenyi Biotec is a leader in cell separation technologies including MACS immunomagnetic sorting, the autoMACS, and the multiMACS platforms widely used in cell therapy manufacturing. It competes with Cytonome's GigaSort in GMP cell isolation workflows.
Beckman Coulter Life Sciences: Beckman Coulter is a major flow cytometry provider with CytoFLEX and Astrios cell sorters serving biopharma and cell therapy markets. It is a broad incumbent competing with Cytonome across research and clinical cell sorting.
Becton Dickinson (BD) Biosciences: BD is the dominant flow cytometry and cell sorting incumbent with the FACSDiscover and BD FACS sorter lines serving pharma, biotech, and academic customers. Cytonome competes directly with BD's GMP-compatible cell sorting instruments for cell therapy manufacturing workflows.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights5 records

Customer concentration

Cytonome compliance and trust

Trust signal

Compliance3 records

Cytonome financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cytonome leadership team

Management profile

Number of profiles

Profiles3 records

Cytonome funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cytonome M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cytonome

What does Cytonome do?

Is Cytonome a public or private company?

Cytonome is a private company. It is classified as corporate owned and is currently operating.

When was Cytonome founded?

Cytonome was founded in 2009. It employs 101 to 250 people.

Where is Cytonome based?

Cytonome is headquartered in Bedford, United States, in the North America region.

How does Cytonome make money?

Three revenue lines are on record. Cell Sorting Equipment Sales are the primary driver. The others are GMP Consumables and cytometry Software.

Who are Cytonome's main competitors?

Emerging players on record are Cellares, Union Biometrica and Curiox Biosystems. 10x Genomics is listed as an others. Sony Biotechnology is listed as a direct peer. Broad incumbents are Bio-Rad Laboratories, Thermo Fisher Scientific (Life Sciences), Miltenyi Biotec, Beckman Coulter Life Sciences and Becton Dickinson (BD) Biosciences.

Does Cytonome have an API?

No public API is recorded for Cytonome.

What industry is Cytonome in?

Cytonome's product category is Cell Sorting Instruments. Its primary akta.pro industry code is HLAAABAG, Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish), with a secondary code of HLAGAIAE, Microscopy, Imaging & Flow Cytometry Instruments. Its NAICS code is 334516 and its SIC code is 3841.